Clinical trials: Sclerosis
Multiple Sclerosis
Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis
Autologous hematopoietic stem cell transplantation (aHSCT) is the only treatment for refractory autoimmune diseases capable of inducing long-term, drug-free and asymptomatic remission.
- Trial name
- NCT06228781
- Testing
- Autologous haemopoietic stem cell transplantation
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University General Hospital
Systemic Sclerosis, Scleroderma
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis
- Conditions
- Systemic Sclerosis, Scleroderma, Interstitial Lung Diseases
- Trial name
- NCT06328777
- Testing
- CABA-201
- Where
- 10 sites in United States
- Volunteers
- 37 people
- Sponsor
- Cabaletta Bio
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
- Conditions
- Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
- Trial name
- NCT06329401
- Testing
- AP01
- Where
- 154 sites in United States, Argentina and 12 more
- Volunteers
- 398 people
- Sponsor
- Avalyn Pharma Inc.
Systemic Sclerosis (SSc)
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
The main purpose of this study is to evaluate the effect and safety of efgartigimod PH20 SC compared to placebo in adults with systemic sclerosis.
- Trial name
- eSScape (NCT06655155)
- Testing
- Efgartigimod PH20 SC
- Where
- 79 sites in United States, Argentina and 22 more
- Volunteers
- 87 people
- Sponsor
- argenx
Progressive Multiple Sclerosis
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS.
- Trial name
- BOBCAT (NCT07139743)
- Testing
- Obecabtagene autoleucel (obe-cel)
- Where
- 7 sites in United States, Spain and 1 more
- Volunteers
- 24 people
- Sponsor
- Autolus Limited
Amyotrophic Lateral Sclerosis
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration…
- Trial name
- ALS (NCT07287397)
- Testing
- VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 36 people
- Sponsor
- Vector Y Therapeutics
Systemic Sclerosis, Sclerodactyly
Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial
Translational studies have demonstrated reduced hyaluronidase activity in the skin of patients with systemic sclerosis. It is thought this may contribute to the progressive fibrosis seen in this disease.
- Trial name
- HASSc (NCT07697274)
- Testing
- Hyaluronidase (Hylenex)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Medical University of South Carolina
Amyotrophic Lateral Sclerosis
Brain-Computer Interface Communication Device for People With ALS
This study compares a wearable brain-computer interface (BCI) communication device with the eye-tracking communication devices that people with ALS already use.
- Trial name
- NCT07871071
- Testing
- Cognixion ONE AR-BCI configuration, Cognixion ONE screen-based BCI configuration, Existing eye-gaze speech generating device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cognixion
Multiple Sclerosis
Dual-Task Balance Training in People With Multiple Sclerosis: a Randomized Feasibility Study
The goal of this randomized controlled feasibility study is to assess whether a balance training program that includes dual-task exercises is feasible in people with multiple sclerosis (MS).
- Trial name
- DTBinMS (NCT07878702)
- Testing
- Dual-task balance training
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Universita di Verona
Relapse Remitting Multiple Sclerosis
Early Versus Delayed Start of Ocrevus Zunovo for Relapsing Multiple Sclerosis
This study will compare starting Ocrevus Zunovo soon after an active episode of relapsing multiple sclerosis (MS) with starting it later.
- Trial name
- STAT (NCT07878923)
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Oklahoma Medical Research Foundation
Multiple Sclerosis
Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue
The overarching aim is to assess the role of microglial activation and norepinephrine transporter binding in pathogenesis of MS-related fatigue, using novel Positron Emission Tomography (PET) radiotracers, [F-18]PBR06 and…
- Trial name
- NCT04144257
- Testing
- [F-18]PBR06, [C-11]Methylreboxetine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brigham and Women's Hospital
Multiple Sclerosis
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
In this study, researchers will learn more about the effects of diroximel fumarate (DRF), also known as VUMERITY®, when taken during pregnancy in people with multiple sclerosis, also known as MS.
- Trial name
- NCT05688436
- Testing
- Diroximel Fumarate, Alemtuzumab, Fingolimod
- Where
- United States
- Volunteers
- 1,178 people
- Sponsor
- Biogen
Multiple Sclerosis
Evaluation of a Self-management Programme to Prevent Falls in People With Multiple Sclerosis
The goal of this randomized controlled trial is to evaluate the effects of a digital group based self-management fall prevention intervention, "Fewer Falls", in people with multiple sclerosis (PwMS).
- Trial name
- Fewer Falls (NCT05789225)
- Testing
- Fall prevention programme, Leaflet
- Where
- Sweden
- Volunteers
- 240 people
- Sponsor
- Karolinska Institutet
Multiple Sclerosis
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary…
- Trial name
- PORTAMENTO (NCT07074886)
- Testing
- Ocrelizumab Test Formulation, Ocrelizumab Reference Formulation
- Where
- 49 sites in United States, Argentina and 7 more
- Volunteers
- 193 people
- Sponsor
- Hoffmann-La Roche
Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, leading to chronic inflammation and damage to organs such as the kidneys, lungs, muscles, nerves, or blood cells.
- Conditions
- Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis, Relapsed/Refractory Idiopathic Inflammatory Myopathies, Relapsed/Refractory sjögren's Syndrome
- Trial name
- NCT07361094
- Testing
- Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy
- Where
- China
- Sponsor
- Beijing Boren Hospital
Depression and Anxiety Symptoms, Multiple Sclerosis
An Online Tailored Cognitive Therapy-Based Intervention for Depression in Multiple Sclerosis: ACTION-MS Online
Individuals with MS experience significantly high levels of depression which are higher than in any other chronic illness or neurological disorder. Depression can occur at any point in the course of the disease.
- Trial name
- ACTION-MS onli (NCT07875309)
- Testing
- ACTION-MS website - an 8-week cognitive behavioural therapy intervention for depression., The 'Health and Wellbeing in MS' website
- Where
- 2 sites in Australia, Canada
- Volunteers
- 240 people
- Sponsor
- University of Melbourne
Amyotrophic Lateral Sclerosis (ALS)
Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)
This is a single-center, open-label, dose-escalation, investigator-initiated pilot study to evaluate the safety, tolerability, dose-limiting toxicity (DLT), and pharmacodynamic signals of orelabrutinib in patients with…
- Trial name
- NCT07875972
- Testing
- Orelabrutinib
- Volunteers
- 12 people
- Sponsor
- Liu Qing
Systemic Sclerosis
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
This is a 52 week, single center, randomized, double-blind, placebo-controlled study. After patients maintain a stable dose of Mycophenolate Mofetil (MMF) for at least 1 month, they will be randomized to treatment with either…
- Trial name
- NCT03844061
- Testing
- Belimumab, Rituximab, MMF
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hospital for Special Surgery, New York
Stroke, Multiple Sclerosis
Evaluation of the NEUROSWING Orthosis on Walking Speed in a Population With Dorsal and/or Plantar Flexor Deficits, With a View to a Reimbursement Application
The aim of this randomized, cross-over, multi-center, intention-to-treat, open-label study study is to determine the benefits of the NEUROSWING device on gait speed in patients with dorsal and/or plantar flexor deficits, compared…
- Conditions
- Stroke, Multiple Sclerosis, Cerebral Palsy, Neuromuscular Deficits
- Trial name
- NS-BOOSST (NCT07108088)
- Testing
- NEUROSWING Orthosis (experimental) : carbon orthosis with an active ankle articulation, Carbon orthosis (control)
- Where
- 2 sites in France
- Volunteers
- 34 people
- Sponsor
- ÖSSUR France
Systemic Sclerosis
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Nerandomilast is being developed to help people with systemic sclerosis by potentially improving symptoms and slowing disease progression.
- Trial name
- VERANDA™-SSc (NCT07497087)
- Testing
- Nerandomilast formulation 1, Nerandomilast formulation 2
- Where
- 248 sites in United States, Argentina and 43 more
- Volunteers
- 448 people
- Sponsor
- Boehringer Ingelheim
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.